Drug Trial Radar · NCT04174157
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Sep 25, 2018
Primary completion
Jun 30, 2038
Study completion Jun 30, 2038
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 22, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the context of advances in treatment options and also to characterize and assess long-term safety and effectiveness of OAV-101.
Conditions
- Spinal Muscular Atrophy (SMA)
Interventions
Prospective observational registryOther
This prospective observational registry will assess long-term outcomes of patients with a diagnosis of SMA.
ZolgensmaDrug
Zolgensma will be given to patients as per normal clinical practice and clinical care will not be mandated by the protocol. As such, the decision to prescribe Zolgensma is separate from the decision to include the patient in this study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in probability of survival of all patients with SMA using Kaplan Meier method to estimateTime frame: Based on information collected at Baseline and every 6 months through 2 years of follow-up, then annually through 15 years of follow up.
- Change from baseline Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) in infants with pre-symptomatic or type I SMATime frame: Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up
- Change from baseline Hammersmith Infant Neurological Examination (HINE) in infants with pre-symptomatic, type I or type II SMATime frame: Baseline and every 6 months through 2 years of follow up, then annually through 15 years of follow up
- Change from baseline in Hammersmith Functional Motor Scale Expanded (HFMSE) for patients with type II and III SMATime frame: Baseline and every 6months through 2 years of follow up, then annually through 15 years of follow up
- Incidence of treatment emergent adverse eventsTime frame: Through 15 years of follow up
- Incidence of treatment emergent serious adverse eventsTime frame: Through 15 years of follow up
- Incidence of treatment emergent adverse events related to therapyTime frame: Through 15 years of follow up
- Incidence of treatment emergent thrombocytopenia, hepatotoxicity and cardiac adverse eventsTime frame: Through 15 years of follow up
Locations
99 sites in 11 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Recruiting
Loma Linda University Health
Loma Linda, California · Completed
Children's Hospital of Los Angeles
Los Angeles, California · Recruiting
University of California Los Angeles Health
Los Angeles, California · Recruiting
Valley Children's Healthcare
Madera, California · Recruiting
Children's Hospital of Orange County
Madera, California · Recruiting
University of California Davis Health System
Sacramento, California · Recruiting
Rady Children's Hospital San Diego
San Diego, California · Recruiting
Children's Hospital Colorado
Aurora, Colorado · Recruiting
Connecticut Children's Medical Center
Farmington, Connecticut · Recruiting
Yale-New Haven Health System
New Haven, Connecticut · Recruiting
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida · Recruiting
Nicklaus Children's Hospital
Miami, Florida · Completed
Adventist Health System - Florida
Orlando, Florida · Completed
Jackson South Medical Center
Palmetto Bay, Florida · Recruiting
Indiana University Health University Hospital (IUHUH)
Indianapolis, Indiana · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
University of Kansas Medical Center
Kansas City, Kansas · Recruiting
University of Louisville
Louisville, Kentucky · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
University of Missouri Health System
Columbia, Missouri · Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri · Recruiting
Atlantic Health System
Morristown, New Jersey · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
The State University of New York
Stony Brook, New York · Recruiting
Duke Health
Durham, North Carolina · Recruiting
Akron Children's Hospital
Akron, Ohio · Completed
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
University Hospitals
Cleveland, Ohio · Completed
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Oklahoma University Medical Center
Oklahoma City, Oklahoma · Completed
Oregon Health and Science University
Portland, Oregon · Recruiting
Penn State Hershey
Hershey, Pennsylvania · Recruiting
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Recruiting
Prisma Health
Greenville, South Carolina · Recruiting
Methodist Le Bonheur Healthcare
Memphis, Tennessee · Recruiting
Child Neurology Consultants of Austin
Austin, Texas · Completed
Children's Health
Dallas, Texas · Completed
Cook Children's
Fort Worth, Texas · Recruiting
Showing 40 of 99 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.